Authorized purpose: Genius AI Detection analyzes compatible digital breast tomosynthesis images to identify and mark soft-tissue densities and calcifications with confidence scores and case scoring for concurrent physician interpretation.
Clinical role
Concurrent physician review with marked findings, confidence scores, and case-level scoring.
Images and patients
Mammography/DBT · Breast; soft-tissue densities and calcifications in digital breast tomosynthesis
Key limitation
Keep in mind: Use is limited to compatible DBT systems and physician confirmation or dismissal of marks and scores; full mammography interpretation remains required.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Genius AI Detection analyzes compatible digital breast tomosynthesis images to identify and mark soft-tissue densities and calcifications with confidence scores and case scoring for concurrent physician interpretation.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast; soft-tissue densities and calcifications in digital breast tomosynthesis Input: Supported digital breast tomosynthesis studies from compatible systems.
Who uses it?Intended users: Qualified interpreting physicians and trained breast-imaging professionals.
What does the software produce?Output: Soft-tissue and calcification marks, confidence scores, and case scores for physician confirmation or dismissal.
What is its most important limitation?Key limitation: Use is limited to compatible DBT systems and physician confirmation or dismissal of marks and scores; full mammography interpretation remains required.
Clinical takeaway. Clinical role: Genius AI Detection analyzes compatible digital breast tomosynthesis images to identify and mark soft-tissue densities and calcifications with confidence scores and case scoring for concurrent physician interpretation.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports an MRMC reader study with 17 readers on 390 cases (106 cancers, 284 negative): average observed AUC 0.825 (95% CI: 0.783, 0.867) with CAD versus 0.794 (95% CI: 0.748, 0.840) without, and average reader sensitivity for cancer cases 75.9% with CAD versus 66.8% without, in analyses that do not control type I error. A standalone study of 764 cases (106 cancers, 658 non-cancer) found comparable fROC detection performance on standard and high-resolution acquisition modes. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Genius AI Detection analyzes compatible digital breast tomosynthesis images to identify and mark soft-tissue densities and calcifications with confidence scores and case scoring for concurrent physician interpretation.
Use is limited to compatible DBT systems and physician confirmation or dismissal of marks and scores; full mammography interpretation remains required.
The exact FDA document reports an MRMC reader study with 17 readers on 390 cases (106 cancers, 284 negative): average observed AUC 0.825 (95% CI: 0.783, 0.867) with CAD versus 0.794 (95% CI: 0.748, 0.840) without, and average reader sensitivity for cancer cases 75.9% with CAD versus 66.8% without, in analyses that do not control type I error. A standalone study of 764 cases (106 cancers, 658 non-cancer) found comparable fROC detection performance on standard and high-resolution acquisition modes. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The study was successfully executed with all 17 readers; the results below represent a per-protocol analysis of the 390 cases (106 cancers, and 284 negative cases) included in the MRMC" … "Based on analyses that do not control type I error and therefore cannot be generalized to specific comparisons outside this particular study,". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports an MRMC reader study with 17 readers on 390 cases (106 cancers, 284 negative): average observed AUC 0.825 (95% CI: 0.783, 0.867) with CAD versus 0.794 (95% CI: 0.748, 0.840) without, and average reader sensitivity for cancer cases 75.9% with CAD versus 66.8% without, in analyses that do not control type I error. A standalone study of 764 cases (106 cancers, 658 non-cancer) found comparable fROC detection performance on standard and high-resolution acquisition modes. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "The study was successfully executed with all 17 readers; the results below represent a per-protocol analysis of the 390 cases (106 cancers, and 284 negative cases) included in the MRMC" … "Based on analyses that do not control type I error and therefore cannot be generalized to specific comparisons outside this particular study,". Read from the exact FDA decision document on 2026-11-14.
Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K201019 FDA evidence package for Genius AI Detection
DesignFDA 510(k) or PMA decision evidence and product verification described in the exact submission.
PopulationBreast; soft-tissue densities and calcifications in digital breast tomosynthesis
Scopeexact submission
Tested versionGenius AI Detection configuration described in K201019
IndependenceSponsor or vendor study
K201019
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K201019 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United States
This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported digital breast tomosynthesis studies from compatible systems.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA package describes compatible DBT systems and physician display of marks, confidence scores, and case scores.
Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes deployment on a stand-alone computer, with a softcopy workstation as the output device. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Output Device Softcopy Workstation same N/A Deployment Stand-alone computer same N/A" … "Genius AI Detection packages all CAD findings derived from the corresponding analysis of a tomosynthesis exam into a DICOM Mammography CAD SR object and distributes it for display on DICOM compliant review workstations.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Soft-tissue and calcification marks, confidence scores, and case scores for physician confirmation or dismissal.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes deployment on a stand-alone computer, with a softcopy workstation as the output device. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Output Device Softcopy Workstation same N/A Deployment Stand-alone computer same N/A" … "Genius AI Detection packages all CAD findings derived from the corresponding analysis of a tomosynthesis exam into a DICOM Mammography CAD SR object and distributes it for display on DICOM compliant review workstations.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA package describes compatible DBT systems and physician display of marks, confidence scores, and case scores.
Exact FDA submission
Checked 2026-09-04
This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Hologic's Breast and Skeletal Products Cybersecurity page states patch validation for Hologic Breast and Skeletal Health systems, MDS2 forms availability, and published security advisories with product impact analyses (including Libwebp, MOVEit, Log4j and Axeda advisories).
Product family
Checked 2026-10-26
Vendor statement, not an attestation. Page scope is Hologic's Breast and Skeletal Health division; this entry is a mammography/DBT product within that division. Exact-release scope is not established.
Only qualified interpreting physicians and trained breast-imaging professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K201019 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use is limited to compatible DBT systems and physician confirmation or dismissal of marks and scores; full mammography interpretation remains required.
Exact FDA submission
Checked 2026-09-04
Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.
exact submission · checked 2026-09-04
FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use is limited to compatible DBT systems and physician confirmation or dismissal of marks and scores; full mammography interpretation remains required.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor K201019 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use is limited to compatible DBT systems and physician confirmation or dismissal of marks and scores; full mammography interpretation remains required.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. digital breast tomosynthesis CAD software limits remain submission-specific.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Authorized purpose: BAC processes screening FFDM and DBT mammograms to detect the presence or absence of breast arterial calcifications at study and breast level and localize detected calcifications for qualified interpreting-physician review.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.